Reading List

The most recent articles from a list of feeds I subscribe to.

Midjourney CEO David Holz says the company's revenue "significantly surpassed" $200M in 2023, and has "gone up" since then, despite its declining web traffic (Jemima McEvoy/The Information)

Jemima McEvoy / The Information:
Midjourney CEO David Holz says the company's revenue “significantly surpassed” $200M in 2023, and has “gone up” since then, despite its declining web traffic  —  Over much of the past year, David Holz, the 37-year-old founder of Midjourney, has devoted himself to a single task …

Pro-AI group Innovation Council Action, praised by David Sacks, plans to spend $100M+ in the US midterms to drive deregulation and support Trump's AI agenda (Alex Isenstadt/Axios)

Alex Isenstadt / Axios:
Pro-AI group Innovation Council Action, praised by David Sacks, plans to spend $100M+ in the US midterms to drive deregulation and support Trump's AI agenda  —  A new pro-AI political operation is jumping into this year's midterms with a plan to spend more than $100 million …

A look at Coinbase One and other insurance-like plans for crypto users that typically exclude coverage for many kinds of account hacks, including phishing scams (Bloomberg)

Bloomberg:
A look at Coinbase One and other insurance-like plans for crypto users that typically exclude coverage for many kinds of account hacks, including phishing scams  —  When Matthew Allan realized nearly $100,000 in Bitcoin was missing from his Coinbase account, he wasn't too worried.

Bluesky CEO Toni Schneider talks about Attie, a new agentic social app built on Bluesky's AT Protocol that uses Claude and lets users build custom feeds (Sarah Perez/TechCrunch)

Sarah Perez / TechCrunch:
Bluesky CEO Toni Schneider talks about Attie, a new agentic social app built on Bluesky's AT Protocol that uses Claude and lets users build custom feeds  —  The team from Bluesky has built another app — and this time, it's not a social network, but an AI assistant that allows you to design …

Hong Kong-listed AI drug discovery company Insilico Medicine and Eli Lilly sign a drug co-development deal worth up to $2.75B, with $115M in upfront payments (Evelyn Cheng/CNBC)

Evelyn Cheng / CNBC:
Hong Kong-listed AI drug discovery company Insilico Medicine and Eli Lilly sign a drug co-development deal worth up to $2.75B, with $115M in upfront payments  —  BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence …